when did the first glp 1 come out GLP-1 Agonists: A Comprehensive Overview History of GLP 1 Agonists

Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024

5,6 Additionally, high glucose levels negatively impact osteoblast function, contributing to bone defects partly through the production of advanced glycation end-products (AGEs), which upregulates sclerostin, an inhibitor of osteoblast activity

Furthermore, alongside the increasing prevalence of related cardiometabolic diseases such as diabetes, obesity and chronic kidney disease (CKD), the number of people with HF has increased to around 64 million globally, amongst whom most are also living with type 2 diabetes or obesity ( Within the past 2 decades, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as effective agents to improve glycaemic control in type 2 diabetes and to reduce body weight in people with overweight or obesity (Sattar et al., 2021

MMIT, 2024